Results

Coming Soon!

Plexus Ventures works with companies of all sizes and capabilities, enhancing revenue growth and profitability to give all clients a competitive edge and secure high-quality partnerships and strategic relationships.

Coming Soon!

Divested Sanofi consumer health brands in APAC to Phoenix Labs

Out-Licensed Elthera Novel ADC therapy for solid tumours to LegoChemBio

Out-Licensed Celon Salmex US rights to Zydus

Out-Licensed Glenmark Ryaltris European rights to Menarini

Divested Cinfa Biotech to Mundipharma

Divested J&J rights to OTC brands to Trimb Healthcare

Sold YouMedical OTC and medical company to Trimb Healthcare

Divested Novartis CH rights to Habitrol® to Dr. Reddy’s

Sold 50% shareholding of Sylphar to Vendis Capital

Divested Glenmark Polish CNS business to Neuraxpharm

Out-Licensed FKB European rights to Humira® Biosimilar to Mylan

Out-Licensed Cynata Tx rights to Cymerus™ MSC cell-therapy to Fujifilm

“...we have come to appreciate the disciplined process which you apply in initiating the programme of speedy and broad contacts with prospective interested parties plus the role which you are able to play...as intermediator at delicate stages within the negotiation process.”

– Former Head of Global Mature Products at Novartis

“Thank you for having helped me to realize my big dream. I truly enjoyed working with you.”

– Founder and CEO, YouMedical BV

“We are very pleased with the advice and support of the Plexus Ventures team, which led to concluding this agreement with FUJIFILM. Plexus’ considerable experience in conducting business with Japan-based companies was a significant factor in achieving this positive outcome.”

– Managing Director, Cynata Therapeutics